Viral vectors for gene therapy

Details Viral vectors for gene therapy Viral vectors for gene therapy

2002-01-04

2008-12-02

Guzo, David (Department: 1636)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093600, C435S320100, C536S023100, C536S023700, C536S023720

Reexamination Certificate

active

07459153

ABSTRACT:
Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.

REFERENCES:
patent: 6054467 (2000-04-01), Gjerset
patent: 6524572 (2003-02-01), Li
patent: 6555367 (2003-04-01), Spence et al.
patent: 1 054 064 (2000-11-01), None
Stone et al., J. Virol., 2005, vol. 79, No. 8, pp. 5090-5104.
Current Biology Ltd., Bramson et al., “The use of adenoviral vectors for gene therapy and gene transfer in vivo”, pp. 590-595, 1995.
Journal of Virology, Segerman et al, “Adenovirus Types 11p and 35p Show HIgh Binding Efficiencies for Committed Hematopoietic Cell Lines and Are infective to These Cell Lines”, pp. 1457-1467, 1999.
Journal of General Virology, W.C. Russell, “Update on adenovirus and its vectors”, pp. 2573-2604, 2000.

Affiliated with

Also associated with

Rating

Viral vectors for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4036588